J.Jpn. Surg. Soc.. 86(6): 697-708, 1985

---

Original article

STUDIES ON EFFECTS OF ADJUVANT CHEMOTHERAPY ON SURVIVAL PERIOD OF THE PATIENTS WITH COLORECTAL CRACINOMA

One hundred and eighty nine patients who had undergone curative resectin of colorectal cancer were treated with a prospective randomized controlled adjuvant chemo-immunotherapy consisting of Tegafur, Adriamycin (ADM), Mitomycin C (MMC) and OK432. One hundred and thirty five patients with Dukes'B and Dukes'C carcinoma were valid for evaluation. Effects of the therapy were estimated by cumurative survival rate. There was no significant survival difference in colonic carcinoma and Dukes'B rectal carcinoma between the treated and control groups. But there was an advantage in two and three years survival for the chemo-immunotherapy in Dukes'C rectal carcinoma (p＜0.1).
Examining the survival rate of Dukes'C rectal carcinoma for each combination of therapeutic agents, the patients treated with Tegafur and ADM had the most favorable survival rate, the patients treated with Tegafur alone had the next favorable one, the patients treated with Tegafur and MMC had the lowest one. The administration of MMC during operation was less effective than the post operative administration in Dukes'C rectal carcinoma.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.